Work

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-157735

Authors: Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas

Institutions: Guy's and St Thomas' NHS Foundation Trust, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, The University of Texas MD Anderson Cancer Center, University Health Network, Memorial Sloan Kettering Cancer Center, University College London Hospitals NHS Foundation Trust, University College London, University of Michigan, U-M Rogel Cancer Center, Azienda Ospedaliero-Universitaria Careggi, Moffitt Cancer Center, Hôpital Saint-Louis, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, Constellation Pharmaceuticals (United States), MorphoSys (Germany)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310099650

FWCI: 1.405

Cites:

Cited by: 11

Related to: 10